Clinical Care Guideline Implementation of Nebulized Tranexamic Acid in Post-Tonsillectomy Hemorrhage

Overview

Post-tonsillectomy hemorrhage (PTH) is one of the most concerning complications after tonsil surgery. Although many cases are minor, any post-operative throat bleeding can become dangerous quickly because blood may be swallowed or aspirated, and swelling or clot formation can threaten the airway. Hospitals therefore need a fast, reliable way to recognize bleeding and begin treatment while deciding whether surgery is necessary.

This article describes the implementation of a clinical care guideline for nebulized tranexamic acid (TXA) in patients presenting with PTH. Tranexamic acid is an antifibrinolytic medication that helps stabilize blood clots by slowing down their breakdown. When delivered by nebulizer, it can be administered quickly in the emergency department and may help reduce bleeding while the patient is being evaluated by otolaryngology.

Why tranexamic acid was considered

Traditionally, treatment for significant PTH has focused on airway assessment, hemodynamic stabilization, direct pressure or bedside measures when possible, and operative control for persistent or severe bleeding. However, not every patient requires immediate return to the operating room. In some cases, bleeding stops or slows enough that observation and supportive care may be appropriate.

Nebulized TXA has gained interest because it can be delivered noninvasively, is relatively easy to administer, and may improve clot stability at the bleeding site. The medication is not a replacement for emergency surgical management when needed, but it can serve as a bridge therapy and potentially reduce the need for operative intervention.

How the clinical care guideline was implemented

The team used a Model for Improvement approach to develop a clinical care guideline, often referred to as a CCG, for TXA administration in PTH. A structured algorithm was created for patients arriving at the Emergency Department with active bleeding or a visible blood clot after tonsillectomy.

Under the protocol, eligible patients received three nebulized TXA treatments. The order set was built into the workflow to improve reliability and reduce delays. This is important in emergency care, where inconsistent awareness and staff turnover can make it difficult to apply new therapies consistently.

Patients were excluded from the protocol if they had severe bleeding, no active bleeding or clot at presentation, or if they could not tolerate nebulized treatment or safely protect their airway. These exclusions reflect the reality that nebulized therapy is only appropriate when the patient is stable enough to wait for a non-operative trial of treatment.

Study design and outcomes

The investigators compared data from two two-year periods: before and after the guideline was introduced. Several outcomes were tracked, including:

– Emergency Department returns for PTH
– Use of the TXA order set
– How often TXA was actually given
– Returns to the operating room
– Secondary returns to the Emergency Department

During the pre-implementation period, there were 2,805 tonsillectomies. In the post-implementation period, there were 5,382 tonsillectomies. The patient age distribution was similar between the two groups, suggesting that the populations were broadly comparable.

Emergency Department returns for bleeding were 70 cases, or 2.5%, before implementation and 155 cases, or 2.9%, after implementation. This difference was not statistically significant, indicating that the overall frequency of post-tonsillectomy bleeding presentations was similar across periods.

Key findings

After the guideline was introduced, 126 patients met inclusion criteria for TXA, representing 81.3% of the eligible group. This suggests that most patients who should have received the therapy were identified appropriately under the new protocol.

Even more striking was the order set utilization rate among patients who received TXA in the Emergency Department: 95.7%. In practical terms, this means the guideline was adopted quickly and integrated well into routine care once it was available.

The most clinically important outcome was operative management. Before the intervention, 35 of 70 patients with PTH, or 50%, returned to the operating room. After implementation, 42 of 155 patients, or 27.1%, required surgery. This reduction was statistically significant, with a p-value of 0.001. The reported absolute risk reduction was 0.320, with a 95% confidence interval of 0.116 to 0.500.

These results suggest that the guideline was associated with fewer operative interventions, although the study design does not prove that nebulized TXA alone caused the reduction. Other factors, such as changes in clinician behavior, better triage, or improvements in overall care processes, may also have contributed.

Clinical meaning of the results

The findings support the idea that a well-designed implementation strategy can make a new therapy usable in everyday emergency care. TXA itself is not new, but translating evidence into consistent practice can be difficult. This study shows that embedding the medication into an order set and using a clear decision algorithm can improve adherence and likely help standardize care.

For clinicians, this may mean faster treatment for patients with post-tonsillectomy bleeding, fewer unnecessary trips to the operating room, and better use of resources. For patients and families, the potential benefit is a less invasive treatment option during a frightening complication.

At the same time, it is important to emphasize that nebulized TXA should not delay surgery in patients with unstable vital signs, airway compromise, brisk hemorrhage, or other signs of severe bleeding. The therapy is best viewed as part of a stepwise management plan, not as a universal substitute for operative control.

Limitations to keep in mind

As with many implementation studies, there are limitations. The data come from a before-and-after comparison, which means changes over time may be influenced by multiple factors besides the guideline itself. The study also does not provide detailed information about dosage specifics, duration of benefit, or long-term safety outcomes in the abstract.

In addition, because the analysis focuses on hospital utilization and return to the operating room, it does not fully capture symptom improvement, patient comfort, or outpatient outcomes. More research, ideally through prospective and multicenter studies, would be helpful to confirm the role of nebulized TXA and define which patients benefit most.

Practical takeaway

This study suggests that implementing a clinical care guideline for nebulized tranexamic acid in post-tonsillectomy hemorrhage can lead to rapid adoption in the Emergency Department and may be associated with fewer returns to the operating room. The protocol appears to be a useful tool for stabilizing selected patients while preserving the ability to escalate care when necessary.

In short, TXA may help bridge the gap between initial bleeding control and definitive treatment, especially when supported by a clear hospital workflow and order set.

Reference

Lavin J, Billings K, Smith A, Patel K, Corboy J, Hazkani I. Clinical Care Guideline Implementation of Nebulized Tranexamic Acid in Post-Tonsillectomy Hemorrhage. Laryngoscope. 2026 May 29. doi: 10.1002/lary.70641. Epub ahead of print. PMID: 42212485.